ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INBX Inhibrx Inc

34.32
-0.13 (-0.38%)
After Hours
Last Updated: 16:15:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 253,758
Bid Price 34.32
Ask Price 34.55
News -
Day High 34.595

Low
14.305

52 Week Range

High
39.79

Day Low 34.2237
Company Name Stock Ticker Symbol Market Type
Inhibrx Inc INBX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.13 -0.38% 34.32 16:15:01
Open Price Low Price High Price Close Price Prev Close
34.40 34.2237 34.595 34.32 34.45
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,271 253,758 $ 34.41 $ 8,731,828 - 14.305 - 39.79
Last Trade Time Type Quantity Stock Price Currency
17:28:58 priorref 37,368 $ 34.32 USD

Inhibrx Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.63B 47.39M - 1.8M -241.36M -5.09 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Inhibrx News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No INBX Message Board. Create One! See More Posts on INBX Message Board See More Message Board Posts

Historical INBX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week34.8135.0834.223734.67314,519-0.49-1.41%
1 Month35.0035.4234.223734.83440,060-0.68-1.94%
3 Months37.6539.7934.223736.14508,134-3.33-8.84%
6 Months17.1839.7914.30532.37603,59317.1499.77%
1 Year20.0939.7914.30528.12504,41714.2370.83%
3 Years18.0547.907.6725.78415,11916.2790.14%
5 Years19.7050.977.6725.87361,23314.6274.21%

Inhibrx Description

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

Your Recent History

Delayed Upgrade Clock